NIH announced 55 recipients of the NIH Director's New Innovator Award, which supports exceptionally creative early career investigators who propose innovative, high-impact projects.
The idea that led to the site-agnostic indication for Keytruda (pembrolizumab) came from the academic oncologists, who ended up defining the biologic mechanism of activity of this class of drugs.
The application for approval of Keytruda (pembrolizumab) was based on internal discussions within FDA as well as working “proactively with the sponsor to submit this application,” said Steven Lemery, associate director, Division of Oncology Products 2, FDA Office of Hematology and Oncology Products.
As part of NCI's ongoing Cancer Moonshot program, the institute, NIH and 11 biopharmaceutical companies launched a five-year public-private research collaboration Oct. 12 designed to advance new immunotherapy treatments.
When he was at Johns Hopkins, there was nothing whatsoever noteworthy about Luis Diaz wandering into Bert Vogelstein's office. Usually, an idea—sometimes even a good idea—was involved.
Earlier this year, when FDA approved Merck's PD-1 inhibitor Keytruda (pembrolizumab) for “site-agnostic” indications, it raised new questions that will likely shape the future of oncology:
For cancer patients, following the initial shock of their diagnosis, thoughts quickly turn to estimating how much precious time they have left with family and friends or whether certain treatments could prolong their life.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
